Unnatural Products key facts
as of Oct 2026- Developer of a computational biology techniques platform designed to engineer peptides that access traditionally undruggable targets.
- Unnatural Products is valued at approximately $170.0M as of Oct 2026, set at its later-stage round, Feb 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $83.5M across 2 recorded rounds; the latest was Early Stage VC ($25.0M) in Jul 2023.
- Notable investors include Gaingels, Calm Ventures, Abstract Ventures, Wing Venture Capital, SGInnovate — 30 tracked in total.
- Unnatural Products has filed 3 Form Ds with the SEC since 2019, most recently Dec 2023 ($25.0M sold to 25 investors).
- Status: Privately Held (backing).
Valued at $170.0M at its later-stage round, Feb 2026. Nothing has traded since.
- ·The complete investor list: 30 names
- ·Watch Unnatural Products: the Monday email on marks, rounds and moves
Unnatural Products funding rounds
2 roundsWho backs Unnatural Products
30+Unnatural Products valuation
Unnatural Products was valued at $170 million at its later-stage round in Feb 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Unnatural Products raised?
Unnatural Products has raised $83.5 million in total; 2 of its rounds are on record. The largest on record was a $5.1 million early-stage round in Sep 2019; the most recent was a $25 million early-stage round in Jul 2023.
Unnatural Products has filed 3 Form Ds with the SEC since 2019, most recently in Dec 2023 ($25 million sold to 25 investors).
Unnatural Products investors
30 investors are on record for Unnatural Products, including Gaingels, Calm Ventures, Abstract Ventures and Wing Venture Capital. By type, the record holds 13 venture capital firms. The early-stage round in Jul 2023 drew 25 investors.
About Unnatural Products
Developer of a computational biology techniques platform designed to engineer peptides that access traditionally undruggable targets. The company's platform uses machine learning to create a parallel chemical synthesis that focuses on the rapid optimization of macrocyclic compounds by harnessing insights from nature, enabling researchers to accelerate the drug discovery process.
- Sector
- Healthcare
- HQ
- Santa Cruz, CA, United States
- Founded
- 2016
- Employees
- 50
- Website
- unnaturalproducts.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.